A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma

NCT06700395 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: TQB2029 injection

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.